MFAP3

Across TCGA pan-cancer cohorts, MFAP3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MFAP3 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher MFAP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MFAP3 expression acts as an unfavorable survival marker.

CESC, LUSC, and TGCT are the cancer types where MFAP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	24	view →
LUSC	OS	Median	All	0.150	0.724	.005	13	view →
TGCT	DFS	Median	All	0.080	0.675	.013	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	DFS	Median	II,III,IV	0.189	0.612	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MFAP3–CESC (OS)

Open the CESC breakdown →